Israeli companies successfully print 3-D stem cell tissue
Israeli-based Nano Dimension and Accellta announce a successful "proof of concept 3-D bioprinter for stem cells" Feasibility study could lead to the printing of "large and complex tissues and organs" and bolster various fields of medicine.
Reuters, Ilan Gattegno, and Israel Hayom staff

A new breakthrough in 3-D printing could bolster regenerative medicine, says Nano Dimension | Photo credit: Reuters, Ilan Gattegno, and Israel Hayom staff

Israel has achieved another scientific breakthrough: Israeli 3-D printer firm Nano Dimension Ltd. has successfully lab-tested a 3-D bioprinter for stem cells, paving the way for the potential printing of large tissues and organs, the company said on Wednesday.

While 3-D printers are used already to create stem cells for research, Nano Dimension said the trial, conducted with Israeli biotech firm Accellta Ltd, showed that its adapted printer could make large volumes of high resolution cells quickly.

Nano Dimension said the results are a "proof of concept 3-D bioprinter for stem cells." According to Nano Dimension CEO Amit Dror, "3-D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control and viability as well as cell availability and bio-ink technologies. By combining our high-speed, high-precision inkjet capabilities with Accellta's stem cell suspension technologies and induced differentiation capabilities led by a world-renowned group of experienced engineers and scientists, we can enable 3-D printing at high resolution and high volumes."

Nano Dimension, which is traded on NASDAQ and the Tel Aviv Stock Exchange, said the technology could ultimately be used to create cells and tissues "for drug discovery, regenerative medicine and research."

"3-D bioprinting enabled by the two companies' technologies means that Nano Dimension and Accellta have the potential to accelerate high fidelity and high viability manufacturing of living cellular products," Nano Dimension said on Wednesday. "Accellta's unique, robust and reproducible suspension-based cell culturing systems produce billions of high-quality stem cells per batch and represent a transformative step in terms of stem cell production. Accellta's technology can deliver large quantities of high quality cells which can be an enabler for printing even large and complex tissues and organs."

Dr. Itzchak Angel, chairman and CEO of Accellta, said on Wednesday, "We hope and believe that this will bring the mutual capabilities and know-how of both companies to create 3-D bioprinting solutions that combine a high-precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells."